Discovery of Inhibitors of Four Bromodomains by Fragment-Anchored Ligand Docking

The high-throughput docking protocol called ALTA-VS (anchor-based library tailoring approach for virtual screening) was developed in 2005 for the efficient in silico screening of large libraries of compounds by preselection of only those molecules that have optimal fragments (anchors) for the protein target. Here we present an updated version of ALTA-VS with a broader range of potential applications. The evaluation of binding energy makes use of a classical force field with implicit solvent in the continuum dielectric approximation. In about 2 days per protein target on a 96-core compute cluster (equipped with Xeon E3-1280 quad core processors at 2.5 GHz), the screening of a library of nearly 77 000 diverse molecules with the updated ALTA-VS protocol has resulted in the identification of 19, 3, 3, and 2 μM inhibitors of the human bromodomains ATAD2, BAZ2B, BRD4(1), and CREBBP, respectively. The success ratio (i.e., number of actives in a competition binding assay in vitro divided by the number of compounds tested) ranges from 8% to 13% in dose-response measurements. The poses predicted by fragment-based docking for the three ligands of the BAZ2B bromodomain were confirmed by protein X-ray crystallography.

[1]  Peter Kolb,et al.  Automated docking of highly flexible ligands by genetic algorithms: A critical assessment , 2004, J. Comput. Chem..

[2]  Peter Kolb,et al.  Discovery of kinase inhibitors by high-throughput docking and scoring based on a transferable linear interaction energy model. , 2008, Journal of medicinal chemistry.

[3]  A. Caflisch,et al.  In Silico Discovery of β-Secretase Inhibitors , 2006 .

[4]  A. Caflisch,et al.  Discovery of cell-permeable non-peptide inhibitors of beta-secretase by high-throughput docking and continuum electrostatics calculations. , 2005, Journal of medicinal chemistry.

[5]  A. Caflisch,et al.  Twenty Crystal Structures of Bromodomain and PHD Finger Containing Protein 1 (BRPF1)/Ligand Complexes Reveal Conserved Binding Motifs and Rare Interactions. , 2016, Journal of medicinal chemistry.

[6]  A. Liwo,et al.  Can cooperativity in hydrophobic association be reproduced correctly by implicit solvation models , 2002 .

[7]  Daniel Vitt,et al.  Virtual high-throughput in silico screening , 2003 .

[8]  Andrew J. Bannister,et al.  Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition. , 2016, Journal of medicinal chemistry.

[9]  S. Zahler,et al.  Three stories on Eph kinase inhibitors: From in silico discovery to in vivo validation. , 2016, European journal of medicinal chemistry.

[10]  Olivier Sperandio,et al.  FAF-Drugs3: a web server for compound property calculation and chemical library design , 2015, Nucleic Acids Res..

[11]  J. Bradner,et al.  Design and Characterization of Bivalent BET Inhibitors , 2016, Nature chemical biology.

[12]  A. Caflisch,et al.  High-Throughput Fragment Docking into the BAZ2B Bromodomain: Efficient in Silico Screening for X-Ray Crystallography. , 2016, ACS chemical biology.

[13]  R. Battistutta,et al.  Different orientations of low-molecular-weight fragments in the binding pocket of a BRD4 bromodomain. , 2013, Acta crystallographica. Section D, Biological crystallography.

[14]  Sereina Riniker,et al.  Better Informed Distance Geometry: Using What We Know To Improve Conformation Generation , 2015, J. Chem. Inf. Model..

[15]  C. Brooks,et al.  Recent advances in the development and application of implicit solvent models in biomolecule simulations. , 2004, Current opinion in structural biology.

[16]  Anthony K. Felts,et al.  On the nonpolar hydration free energy of proteins: surface area and continuum solvent models for the solute-solvent interaction energy. , 2003, Journal of the American Chemical Society.

[17]  Jeremy C. Smith,et al.  Can the calculation of ligand binding free energies be improved with continuum solvent electrostatics and an ideal‐gas entropy correction? , 2002, J. Comput. Chem..

[18]  Piotr Cieplak,et al.  Molecular dynamics and free energy analyses of cathepsin D-inhibitor interactions: insight into structure-based ligand design. , 2002, Journal of medicinal chemistry.

[19]  J. Apostolakis,et al.  Continuum Electrostatic Energies of Macromolecules in Aqueous Solutions , 1997 .

[20]  R. Prinjha,et al.  Clinical progress and pharmacology of small molecule bromodomain inhibitors. , 2016, Current opinion in chemical biology.

[21]  S. Knapp,et al.  CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses , 2015, Proceedings of the National Academy of Sciences.

[22]  B. Shoichet,et al.  Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B. , 2002, Journal of medicinal chemistry.

[23]  Xavier Barril,et al.  rDock: A Fast, Versatile and Open Source Program for Docking Ligands to Proteins and Nucleic Acids , 2014, PLoS Comput. Biol..

[24]  A. Caflisch,et al.  The "Gatekeeper" Residue Influences the Mode of Binding of Acetyl Indoles to Bromodomains. , 2016, Journal of medicinal chemistry.

[25]  P. Filippakopoulos,et al.  Functions of bromodomain-containing proteins and their roles in homeostasis and cancer , 2017, Nature Reviews Molecular Cell Biology.

[26]  Alexander D. MacKerell,et al.  Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone φ, ψ and side-chain χ(1) and χ(2) dihedral angles. , 2012, Journal of chemical theory and computation.

[27]  Alexander D. MacKerell,et al.  Automation of the CHARMM General Force Field (CGenFF) I: Bond Perception and Atom Typing , 2012, J. Chem. Inf. Model..

[28]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[29]  John J. Irwin,et al.  ZINC 15 – Ligand Discovery for Everyone , 2015, J. Chem. Inf. Model..

[30]  Nathan Brown,et al.  Druggability Analysis and Structural Classification of Bromodomain Acetyl-lysine Binding Sites , 2012, Journal of medicinal chemistry.

[31]  A. Caflisch,et al.  Binding Mode of Acetylated Histones to Bromodomains: Variations on a Common Motif , 2015, ChemMedChem.

[32]  A. Gingras,et al.  Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family , 2012, Cell.

[33]  Structure-based approaches towards identification of fragments for the low-druggability ATAD2 bromodomain , 2014 .

[34]  A. Caflisch,et al.  Fragment-Based Flexible Ligand Docking by Evolutionary Optimization , 2001, Biological chemistry.

[35]  N. Foloppe,et al.  Towards predictive ligand design with free-energy based computational methods? , 2006, Current medicinal chemistry.

[36]  Chris Abell,et al.  Targeting Low-Druggability Bromodomains: Fragment Based Screening and Inhibitor Design against the BAZ2B Bromodomain , 2013, Journal of medicinal chemistry.

[37]  M. Oppikofer,et al.  A Subset of Human Bromodomains Recognizes Butyryllysine and Crotonyllysine Histone Peptide Modifications. , 2015, Structure.

[38]  Amedeo Caflisch,et al.  Flaviviral protease inhibitors identified by fragment-based library docking into a structure generated by molecular dynamics. , 2009, Journal of medicinal chemistry.

[39]  A. Caflisch,et al.  A double‐headed cathepsin B inhibitor devoid of warhead , 2008, Protein science : a publication of the Protein Society.

[40]  Andrew J. Bannister,et al.  A Chemical Probe for the ATAD2 Bromodomain. , 2016, Angewandte Chemie.

[41]  S. Knapp,et al.  Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery. , 2011, Molecular bioSystems.

[42]  Shaomeng Wang,et al.  How Does Consensus Scoring Work for Virtual Library Screening? An Idealized Computer Experiment , 2001, J. Chem. Inf. Comput. Sci..

[43]  A. Caflisch,et al.  Efficient electrostatic solvation model for protein‐fragment docking , 2001, Proteins.

[44]  A. Caflisch,et al.  Structure‐based tailoring of compound libraries for high‐throughput screening: Discovery of novel EphB4 kinase inhibitors , 2008, Proteins.

[45]  Daniel Cappel,et al.  Accurate Binding Free Energy Predictions in Fragment Optimization , 2015, J. Chem. Inf. Model..

[46]  W. Im,et al.  Continuum solvation model: Computation of electrostatic forces from numerical solutions to the Poisson-Boltzmann equation , 1998 .

[47]  J. Irwin,et al.  An Aggregation Advisor for Ligand Discovery. , 2015, Journal of medicinal chemistry.

[48]  Harren Jhoti,et al.  Twenty years on: the impact of fragments on drug discovery , 2016, Nature Reviews Drug Discovery.

[49]  Chris Morley,et al.  Open Babel: An open chemical toolbox , 2011, J. Cheminformatics.

[50]  Philip R. Evans,et al.  How good are my data and what is the resolution? , 2013, Acta crystallographica. Section D, Biological crystallography.

[51]  Kay Diederichs,et al.  Assessing and maximizing data quality in macromolecular crystallography. , 2015, Current opinion in structural biology.

[52]  A. Caflisch,et al.  Molecular dynamics in drug design. , 2015, European journal of medicinal chemistry.

[53]  A. Caflisch,et al.  Discovery of BAZ2A Bromodomain Ligands , 2017, bioRxiv.

[54]  S. Knapp,et al.  Targeting bromodomains: epigenetic readers of lysine acetylation , 2014, Nature Reviews Drug Discovery.

[55]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[56]  J A McCammon,et al.  Determinants of ligand binding to cAMP-dependent protein kinase. , 1999, Biochemistry.

[57]  John J. Wendoloski,et al.  Electrostatic binding energy calculation using the finite difference solution to the linearized Poisson‐Boltzmann equation: Assessment of its accuracy , 1996 .

[58]  A. Caflisch,et al.  Virtual screen to NMR (VS2NMR): Discovery of fragment hits for the CBP bromodomain. , 2017, Bioorganic & medicinal chemistry letters.

[59]  Randy J. Read,et al.  Acta Crystallographica Section D Biological , 2003 .

[60]  Stefan Knapp,et al.  Bromodomains as therapeutic targets , 2011, Expert Reviews in Molecular Medicine.

[61]  Amedeo Caflisch,et al.  Derivatives of 3-Amino-2-methylpyridine as BAZ2B Bromodomain Ligands: In Silico Discovery and in Crystallo Validation. , 2016, Journal of medicinal chemistry.

[62]  Seishi Shimizu,et al.  Anti‐cooperativity and cooperativity in hydrophobic interactions: Three‐body free energy landscapes and comparison with implicit‐solvent potential functions for proteins , 2002, Proteins.

[63]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[64]  D. Case,et al.  Generalized born models of macromolecular solvation effects. , 2000, Annual review of physical chemistry.

[65]  Jianpeng Ma,et al.  CHARMM: The biomolecular simulation program , 2009, J. Comput. Chem..

[66]  Andrew C Good,et al.  Diving into the Water: Inducible Binding Conformations for BRD4, TAF1(2), BRD9, and CECR2 Bromodomains. , 2016, Journal of medicinal chemistry.

[67]  Woody Sherman,et al.  Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments , 2013, Journal of Computer-Aided Molecular Design.

[68]  J. Irwin,et al.  Docking Screens for Novel Ligands Conferring New Biology. , 2016, Journal of medicinal chemistry.

[69]  B Honig,et al.  On the calculation of binding free energies using continuum methods: Application to MHC class I protein‐peptide interactions , 1997, Protein science : a publication of the Protein Society.

[70]  Alexander D. MacKerell,et al.  Automation of the CHARMM General Force Field (CGenFF) II: Assignment of Bonded Parameters and Partial Atomic Charges , 2012, J. Chem. Inf. Model..

[71]  Wilfred F. van Gunsteren,et al.  The importance of solute-solvent van der Waals interactions with interior atoms of biopolymers. , 2001 .

[72]  A. Caflisch,et al.  Discovery of CREBBP Bromodomain Inhibitors by High-Throughput Docking and Hit Optimization Guided by Molecular Dynamics. , 2016, Journal of medicinal chemistry.